AstraZeneca AB — Sponsor Intelligence | 280 EU Trials

Filter these 280 trials by condition, phase, country and more.

Open in Search →

280 Registered trials

84 Recruiting

179 Completed trials

25 Countries active

207 Unique IMPs

100% Results reported

Phase III

Phase II

Phase I (Other)

Phase III: 132 Phase II/III: 2 Phase II: 58 Phase I/II: 13 Phase III/IV: 2 Phase IV: 3 Phase I: 12 Phase I (Other): 40 Phase I (FiH): 17 Other: 1

Oversight events:

12 serious breaches 33 temporary halts 6 urgent safety measures 1 unexpected event 6 corrective measures across 27 trials

View oversight register →

100%

179 of 179 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Non-small cell lung cancer 14 Asthma 12 Chronic obstructive pulmonary disease 11 Chronic kidney disease 6 Triple negative breast cancer 5 Systemic lupus erythematosus 5 Hepatocellular carcinoma 4 Breast cancer 4 Ovarian cancer 4 Non-small cell lung cancer metastatic 4 Prostate cancer 3 Rheumatoid arthritis 3

Top IMPs

DURVALUMAB 46 RILVEGOSTOMIG 22 DATOPOTAMAB DERUXTECAN 18 TRASTUZUMAB DERUXTECAN 18 INFLIXIMAB 16 MYCOPHENOLATE MOFETIL 16 OSIMERTINIB 16 VOLRUSTOMIG 12 OLAPARIB 11 TREMELIMUMAB 11 BENRALIZUMAB 8 CAMIZESTRANT 8

All trials — page 2

280 total

A study of anifrolumab in children and adolescents (5 to < 18 years old) with moderate to severe lupus to find the appropriate anifrolumab d… Recruiting

2022-502289-25-00 Phase III 6 countries ANIFROLUMAB
AZD5305 vs Placebo in Men with Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents. Recruiting

2023-504214-30-00 Phase III 11 countries ABIRATERONE ACETATE; DAROLUTAMIDE; ENZALUTAMIDE; SARUPARIB
Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen (TILIA). Recruiting

2023-507031-38-00 Phase III 14 countries TOZORAKIMAB
A trial to learn how safe durvalumab with chemotherapy is and how well it works in adults with muscle-invasive bladder cancer Recruiting

2024-519246-75-01 Phase II 4 countries DURVALUMAB
A Study to evaluate the long-term safety and tolerability of tozorakimab in patients with chronic obstructive pulmonary disease (COPD) and a… Recruiting

2025-523690-41-00 Phase III 1 country
AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer (TREVI-OC-01) Recruiting

2025-520466-22-00 Phase III 10 countries AZD5335
A Phase IIb study to evaluate the effect of combination of dapagliflozin and baxdrostat compared with baxdrostat alone in participants with … Recruiting

2025-522407-23-00 Phase II 2 countries BAXDROSTAT; DAPAGLIFLOZIN
A trial to learn how safe the combination of rilvegostomig and chemotherapy is and how well it works compared to durvalumab and chemotherapy… Recruiting

2025-523085-24-00 Phase III 7 countries DURVALUMAB; RILVEGOSTOMIG
A trial to learn how effective and safe datopotamab deruxtecan (Dato-DXd) is compared to docetaxel and how well Dato-DXd works in adults wit… Recruiting

2024-520101-39-00 Phase III 8 countries DATOPOTAMAB DERUXTECAN
(Title in lay language): A trial to learn how safe AZD0516 is and how well it works with and without other cancer treatments in adults with … Recruiting

2024-520026-11-00 Phase I (FiH) 3 countries 6-FLUORO-5-[4-[(5-FLUORO-2-METHYL-3-OXO-4H-QUINOXALIN-6-YL)METHYL]PIPERAZIN-1-YL…
Phase III Study of Rilvegostomig in Combination withBevacizumab with or without Tremelimumab as First-lineTreatment of Hepatocellular Carcin… Recruiting

2024-518210-81-00 Phase III 6 countries RILVEGOSTOMIG; TREMELIMUMAB
Prevention of Recurrent C. difficile Infection Study with AZD5148 Monoclonal Antibody Recruiting

2025-521416-19-00 Phase II 8 countries HUMANISED IGG1 KAPPA (YTE) MONOCLONAL ANTIBODY AGAINST CLOSTRIDIOIDES DIFFICILE,…
A trial to learn how well AZD4144 works, how safe it is, and how it moves throughout the body over time in adults with acute kidney injury c… Recruiting

2025-522232-13-00 Phase II 9 countries AZD4144
A trial to learn how safe AZD0486 is and how well it works in older or physically weak adults with large B-cell lymphoma when given after R-… Recruiting

2025-522029-37-00 Phase III 2 countries CYCLOPHOSPHAMIDE; DOXORUBICIN HYDROCHLORIDE; HUMAN IGG4 KAPPA MONOCLONAL ANTIBOD…
A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants with Advanced Solid Tumors Previo… Recruiting

2025-521614-26-00 Phase I (Other) 1 country
A trial to learn how safe Dato-DXd is and how well it works in people with NSCLC that has advanced after receiving osimertinib Recruiting

2024-511362-37-00 Phase III 7 countries DATOPOTAMAB DERUXTECAN; OSIMERTINIB
A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer Recruiting

2025-521904-23-00 Phase II 3 countries DATOPOTAMAB DERUXTECAN
A study to investigate the effect of capivasertib on the pharmacokinetics of oral dextromethorphan (CYP2D6) in healthy participants Recruiting

2025-523995-21-00 Phase I (Other) 1 country
A trial to learn how safe AZD5335 is and if a drug called itraconazole changes how AZD5335 moves through the body over time in adults with o… Recruiting

2025-522731-34-00 Phase I (Other) 3 countries
A trial to learn how safe AZD4512 is and how it works in the bodies of people with B-cell acute lymphoblastic leukemia (B-ALL) Recruiting

2025-522372-93-00 Phase I (FiH) 1 country AZD4512
A trial to learn how safe AZD4360 is, how well it works, and how it moves throughout the body over time in adults with advanced solid tumors Recruiting

2024-518281-27-00 Phase I (FiH) 1 country AZD4360
A trial to learn how safe AZD4512 is with and without other cancer drugs and how it works in the bodies of people with B-cell non-Hodgkin ly… Recruiting

2025-522371-29-00 Phase I (FiH) 1 country AZD4512
A trial to learn how well AZD0292 works, how safe it is, and how it moves throughout the body over time in people with bronchiectasis and ch… Recruiting

2025-523009-14-00 Phase II 8 countries AZD0292
A study to evaluate the impact on metastases-free survival with the addition of saruparib vs placebo to a standard radiotherapy androgen dep… Recruiting

2024-513586-39-00 Phase III 11 countries ABIRATERONE ACETATE; SARUPARIB

Showing 25–48 of 280 trials

← All sponsors A–Z